Galectin Therapeutics (GALT) Short Interest Ratio & Short Volume $2.80 -0.09 (-3.11%) Closing price 04:00 PM EasternExtended Trading$2.95 +0.15 (+5.36%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Galectin Therapeutics Short Interest DataGalectin Therapeutics (GALT) has a short interest of 7.79 million shares, representing 17.94% of the float (the number of shares available for trading by the public). This marks a -12.96% decrease in short interest from the previous month. The short interest ratio (days to cover) is 13.6, indicating that it would take 13.6 days of the average trading volume of 420,032 shares to cover all short positions.Current Short Interest7,790,000 sharesPrevious Short Interest8,950,000 sharesChange Vs. Previous Month-12.96%Dollar Volume Sold Short$16.44 millionShort Interest Ratio13.6 Days to CoverLast Record DateJune 30, 2025Outstanding Shares63,290,000 sharesFloat Size43,420,000 sharesShort Percent of Float17.94%Today's Trading Volume443,809 sharesAverage Trading Volume420,032 sharesToday's Volume Vs. Average106% Short Selling Galectin Therapeutics? Sign up to receive the latest short interest report for Galectin Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartGALT Short Interest Over TimeGALT Days to Cover Over TimeGALT Percentage of Float Shorted Over Time Galectin Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/20257,790,000 shares $16.44 million -13.0%17.9%13.6 $2.11 6/15/20258,950,000 shares $12.26 million +0.6%20.6%16.9 $1.37 5/31/20258,900,000 shares $11.66 million +2.7%20.4%42.6 $1.31 5/15/20258,670,000 shares $11.44 million +2.4%19.8%40.6 $1.32 4/30/20258,470,000 shares $11.60 million +1.3%19.4%35.3 $1.37 4/15/20258,360,000 shares $11.20 million +6.0%19.2%33.9 $1.34 3/31/20257,890,000 shares $9.63 million -3.2%18.1%28.4 $1.22 3/15/20258,150,000 shares $13.69 million +0.4%18.9%12.8 $1.68 2/28/20258,120,000 shares $12.75 million +5.2%18.9%11.3 $1.57 2/15/20257,720,000 shares $10.89 million -3.3%18.0%10.6 $1.41 Get the Latest News and Ratings for GALT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20257,980,000 shares $9.98 million -2.2%18.5%11.2 $1.25 1/15/20258,160,000 shares $10.44 million +1.5%18.9%11.8 $1.28 12/31/20248,040,000 shares $10.37 million -2.8%18.5%12.1 $1.29 12/15/20248,270,000 shares $17.45 million +41.1%19.0%16.7 $2.11 11/30/20245,860,000 shares $16.94 million +2.8%13.5%26.7 $2.89 11/15/20245,700,000 shares $15.79 million +3.3%13.1%40.3 $2.77 10/31/20245,520,000 shares $13.63 million +1.1%12.8%42.9 $2.47 10/15/20245,460,000 shares $14.20 million +1.5%12.6%45 $2.60 9/30/20245,380,000 shares $14.80 million +2.3%12.4%43.7 $2.75 9/15/20245,260,000 shares $15.10 million +4.0%12.2%30.9 $2.87 8/31/20245,060,000 shares $13.64 million +1.0%11.7%29.8 $2.70 8/15/20245,010,000 shares $10.97 million +6.4%11.6%30.3 $2.19 7/31/20244,710,000 shares $11.78 million +3.1%10.9%26.7 $2.50 7/15/20244,570,000 shares $10.88 million +14.0%10.7%24 $2.38 6/30/20244,010,000 shares $9.06 million +1.5%9.4%18 $2.26 6/15/20243,950,000 shares $10.35 million +3.4%9.3%20.3 $2.62 5/31/20243,820,000 shares $10.39 million +2.4%9.0%20.2 $2.72 5/15/20243,730,000 shares $11.41 million +19.6%8.8%20.4 $3.06 4/30/20243,120,000 shares $10.95 million +13.9%7.4%18.8 $3.51 4/15/20242,740,000 shares $10.71 million +21.8%6.5%18.7 $3.91 3/31/20242,250,000 shares $5.38 million +5.1%5.3%21.3 $2.39 3/15/20242,140,000 shares $4.41 million +1.9%5.1%29.4 $2.06 2/29/20242,100,000 shares $4.11 million +1.0%5.0%30.6 $1.96 2/15/20242,080,000 shares $3.64 million No Change4.9%33.3 $1.75 1/31/20242,080,000 shares $3.52 million -0.5%4.9%32.8 $1.69 1/15/20242,090,000 shares $3.85 million -1.0%5.0%34 $1.84 12/31/20232,110,000 shares $3.50 million -0.9%5.0%33.8 $1.66 12/15/20232,130,000 shares $3.41 million +1.0%5.0%33.7 $1.60 11/30/20232,110,000 shares $4.11 million +8.2%5.0%36.9 $1.95 11/15/20231,950,000 shares $3.65 million No Change4.6%37.3 $1.87Altucher: Turn $900 into $108,000 in just 12 months? (Ad)Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this marks the beginning of “Trump’s Great Gain,” a new crypto bull phase driven by emerging federal policies. He believes certain altcoins could turn $900 into $108,000 — and reveals everything in a new presentation.See Altucher’s Great Gain gameplan here 10/31/20231,950,000 shares $3.98 million +3.7%4.7%39.3 $2.04 10/15/20231,880,000 shares $3.78 million -5.5%4.5%35.9 $2.01 9/30/20231,990,000 shares $3.82 million -1.5%4.8%36.1 $1.92 9/15/20232,020,000 shares $3.56 million No Change4.8%40.3 $1.76 8/31/20232,020,000 shares $3.54 million +2.5%4.8%35.7 $1.75 8/15/20231,970,000 shares $3.15 million -3.4%4.7%32.2 $1.60 7/31/20232,040,000 shares $3.06 million -1.5%4.8%33.6 $1.50 7/15/20232,070,000 shares $3.37 million -3.3%4.9%35 $1.63 6/30/20232,140,000 shares $3.08 million +2.9%5.1%37.4 $1.44 6/15/20232,080,000 shares $3.04 million -0.5%4.9%35.4 $1.46 5/31/20232,090,000 shares $3.28 million -1.4%5.0%40.3 $1.57 5/15/20232,120,000 shares $3.48 million +0.5%5.0%29.1 $1.64 4/30/20232,110,000 shares $3.71 million No Change5.0%22.8 $1.76 4/15/20232,110,000 shares $4.24 million No Change5.0%21.6 $2.01 3/31/20232,110,000 shares $4.43 million -0.5%5.0%21.4 $2.10 3/15/20232,120,000 shares $4.03 million +5.0%5.0%18.5 $1.90 2/28/20232,020,000 shares $4.18 million No Change4.8%17.2 $2.07 2/15/20232,020,000 shares $2.91 million +3.1%4.8%20.5 $1.44 1/31/20231,960,000 shares $2.27 million -1.5%4.6%19.7 $1.16 1/15/20231,990,000 shares $2.27 million -0.5%4.7%24.8 $1.14 12/30/20222,000,000 shares $2.26 million -1.5%4.7%22.7 $1.13 12/15/20222,030,000 shares $2.35 million +0.5%4.8%26.6 $1.16 11/30/20222,020,000 shares $2.57 million -0.5%4.8%32.8 $1.27 11/15/20222,030,000 shares $2.52 million -1.5%4.8%33.7 $1.24 10/31/20222,060,000 shares $2.84 million -3.7%4.9%33.9 $1.38 10/15/20222,140,000 shares $3.47 million +3.4%5.0%29.6 $1.62 9/30/20222,070,000 shares $3.37 million No Change4.9%29.8 $1.63 9/15/20222,070,000 shares $3.71 million -1.4%4.9%26.7 $1.79 8/31/20222,100,000 shares $3.99 million -1.4%4.9%24.9 $1.90 8/15/20222,130,000 shares $4.64 million -0.5%5.0%22.6 $2.18 7/31/20222,140,000 shares $4.84 million +0.9%5.0%21.4 $2.26 7/15/20222,120,000 shares $3.50 million -2.8%5.0%22.5 $1.65 6/30/20222,180,000 shares $2.86 million -1.8%5.1%19.7 $1.31 6/15/20222,220,000 shares $2.82 million +3.7%6.5%18.9 $1.27 5/31/20222,140,000 shares $2.76 million -1.4%5.0%18.8 $1.29 5/15/20222,170,000 shares $2.95 million -9.6%5.1%19.7 $1.36 4/30/20222,400,000 shares $3.72 million +7.6%5.6%23 $1.55 4/15/20222,230,000 shares $3.88 million +9.9%5.2%19.8 $1.74 3/31/20222,030,000 shares $3.27 million +2.5%4.8%20.1 $1.61 3/15/20221,980,000 shares $3.45 million +7.0%4.6%17.6 $1.74 2/28/20221,850,000 shares $3.46 million -5.6%4.3%14.7 $1.87 2/15/20221,960,000 shares $4.06 million -1.0%4.6%14.5 $2.07 1/31/20221,980,000 shares $3.82 million No Change4.6%12.7 $1.93 1/15/20221,980,000 shares $4.00 million +4.2%4.6%12.5 $2.02 12/31/20211,900,000 shares $3.93 million -11.6%4.4%11.8 $2.07 12/15/20212,150,000 shares $4.84 million -4.4%5.0%12.4 $2.25 11/30/20212,250,000 shares $5.92 million -1.8%5.3%11.2 $2.63 11/15/20212,290,000 shares $6.55 million +5.5%5.4%9.3 $2.86 10/29/20212,170,000 shares $6.88 million -11.4%5.1%8 $3.17 10/15/20212,450,000 shares $8.26 million +3.8%5.7%6.9 $3.37Altucher: Turn $900 into $108,000 in just 12 months? (Ad)Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this marks the beginning of “Trump’s Great Gain,” a new crypto bull phase driven by emerging federal policies. He believes certain altcoins could turn $900 into $108,000 — and reveals everything in a new presentation.See Altucher’s Great Gain gameplan here 9/30/20212,360,000 shares $9.16 million -13.9%5.5%4.7 $3.88 9/15/20212,740,000 shares $10.22 million -7.4%6.4%1.3 $3.73 8/31/20212,960,000 shares $11.63 million -18.2%7.0%1.3 $3.93 8/13/20213,620,000 shares $12.24 million +17.5%8.5%1.6 $3.38 7/30/20213,080,000 shares $8.47 million -9.9%7.4%1.4 $2.75 7/15/20213,420,000 shares $8.86 million +25.7%8.2%1.3 $2.59 6/30/20212,720,000 shares $8.70 million -40.6%6.5%0.7 $3.20 6/15/20214,580,000 shares $16.03 million +11.2%11.0%1.8 $3.50 5/28/20214,120,000 shares $16.36 million -22.9%10.0%1.6 $3.97 5/14/20215,340,000 shares $22.48 million -2.2%12.9%2.1 $4.21 4/30/20215,460,000 shares $23.15 million +12.4%13.4%2.2 $4.24 4/15/20214,860,000 shares $11.47 million +1.9%12.0%2.3 $2.36 3/31/20214,770,000 shares $9.68 million +2.4%11.8%7.7 $2.03 3/15/20214,660,000 shares $10.76 million +0.7%11.5%14.8 $2.31 2/26/20214,630,000 shares $10.60 million -0.9%11.4%14.4 $2.29 2/12/20214,670,000 shares $11.25 million +3.6%11.5%15.1 $2.41 1/29/20214,510,000 shares $8.93 million -0.4%11.1%15.9 $1.98 1/15/20214,530,000 shares $10.10 million -5.0%11.2%18.8 $2.23 12/31/20204,770,000 shares $10.97 million -3.3%11.8%21.3 $2.30 12/15/20204,930,000 shares $12.47 million -2.2%12.2%15.3 $2.53 11/30/20205,040,000 shares $13.36 million -2.0%12.4%16.2 $2.65 11/15/20205,140,000 shares $14.14 million -1.7%12.7%17.2 $2.75 10/30/20205,230,000 shares $13.65 million -2.2%12.9%17 $2.61 10/15/20205,350,000 shares $14.77 million +0.8%13.2%17.5 $2.76 9/30/20205,310,000 shares $14.18 million +4.1%13.0%18.8 $2.67 9/15/20205,100,000 shares $14.94 million -3.8%12.5%29.7 $2.93 8/31/20205,300,000 shares $14.05 million -1.3%13.0%30.8 $2.65 8/14/20205,370,000 shares $16.49 million -2.2%13.1%30.2 $3.07 7/31/20205,490,000 shares $14.33 million -1.4%13.4%29.8 $2.61 GALT Short Interest - Frequently Asked Questions What is Galectin Therapeutics' current short interest? Short interest is the volume of Galectin Therapeutics shares that have been sold short but have not yet been covered or closed out. As of June 30th, traders have sold 7,790,000 shares of GALT short. 17.94% of Galectin Therapeutics' shares are currently sold short. Learn More on Galectin Therapeutics' current short interest. What is a good short interest ratio for Galectin Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GALT shares currently have a short interest ratio of 14.0. Learn More on Galectin Therapeutics's short interest ratio. Which institutional investors are shorting Galectin Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Galectin Therapeutics: Jane Street Group LLC, Caption Management LLC, HAP Trading LLC, Affinity Asset Advisors LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Galectin Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 17.94% of Galectin Therapeutics' floating shares are currently sold short. Is Galectin Therapeutics' short interest increasing or decreasing? Galectin Therapeutics saw a decline in short interest in June. As of June 30th, there was short interest totaling 7,790,000 shares, a decline of 13.0% from the previous total of 8,950,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Galectin Therapeutics' float size? Galectin Therapeutics currently has issued a total of 63,290,000 shares. Some of Galectin Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Galectin Therapeutics currently has a public float of 43,420,000 shares. How does Galectin Therapeutics' short interest compare to its competitors? 17.94% of Galectin Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Galectin Therapeutics: Keros Therapeutics, Inc. (16.00%), Tilray Brands, Inc. (20.64%), Mind Medicine (MindMed) Inc. (15.33%), Organogenesis (15.93%), Zevra Therapeutics, Inc. (3.69%), Tyra Biosciences, Inc. (0.06%), Taysha Gene Therapies, Inc. (0.70%), Opthea Limited Unsponsored ADR (0.36%), Bicycle Therapeutics PLC Sponsored ADR (4.87%), Kura Oncology, Inc. (9.70%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks. What does it mean to sell short Galectin Therapeutics stock? Short selling GALT is an investing strategy that aims to generate trading profit from Galectin Therapeutics as its price is falling. GALT shares are trading down $0.09 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Galectin Therapeutics? A short squeeze for Galectin Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GALT, which in turn drives the price of the stock up even further. How often is Galectin Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GALT, twice per month. The most recent reporting period available is June, 30 2025. More Short Interest Resources from MarketBeat Related Companies KROS Short Interest Data TLRY Short Interest Data MNMD Short Interest Data ORGO Short Interest Data ZVRA Short Interest Data TYRA Short Interest Data TSHA Short Interest Data OPT Short Interest Data BCYC Short Interest Data KURA Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GALT) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | SponsoredWill I be blacklisted?Porter Stansberry says a financial force bigger than 9/11 or COVID is already ripping through America — and mo...Porter & Company | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GALT Stock Alerts